Axion Biosystems - About the company
Axion Biosystems is an acquired company based in Atlanta (United States), founded in 2007. It operates as a Develops multi-electrode array technology to provide access to cellular information analysis. Axion Biosystems has raised $20.3M in funding from GRA Venture Fund. The company has 80 active competitors, including 27 funded and 9 that have exited. Its top competitors include companies like 10X Genomics, Mission Bio and LUMICKS.
Company Details
Axion BioSystems develops multi-electrode array technology to provide access to cellular information analysis for research, clinical, and drug discovery markets. It offers single-well systems, stimulating and recording channels, channel systems, multi-well systems, and integrated circuits for the elimination of stimulation artifacts.
- Website
- axionbiosystems.com
- Email ID
- *****@axionbio.com
Key Metrics
Founded Year
2007
Location
Atlanta, United States
Stage
Acquired
Total Funding
$20.3M in 14 rounds
Latest Funding Round
Investors
Ranked
9th among 80 active competitors
Employee Count
121 as on Apr 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Acquired by Summa Equity (Jul 15, 2021)
Legal entities associated with Axion Biosystems
Axion Biosystems is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
AXION CIN: 275079434 , United States, Active | Dec 31, 1999 | - | 14 (As on Dec 31, 2017) | - |
Axion Biosystems, Inc. CIN: 4389233 , United States, Active | - | 24 (As on Dec 31, 2013) | - |
Axion Biosystems's acquisition details
Axion Biosystems got acquired by Summa Equity on Jul 15, 2021.
Click here to take a look at Axion Biosystems's acquisition in detail
Sign up to download Axion Biosystems' company profile
Axion Biosystems's funding and investors
Axion Biosystems has raised a total funding of $20.3M over 14 rounds. Its first funding round was on Jul 07, 2008. Its latest funding round was a Grant (prize money) round on Jan 01, 2020 for $*****. 1 investor participated in its latest round. Axion Biosystems has 5 institutional investors.
Here is the list of recent funding rounds of Axion Biosystems:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 01, 2020 | 9294964 | Grant (prize money) | 8265043 | 2109178 | 4390311 | 5549648 |
Sep 27, 2018 | 3230099 | Series C | 5985584 | 5282338 | 5459837 | 4823144 |
May 16, 2016 | 2208531 | Series C | 2684969 | 2875579 | 1983857 |
Access funding benchmarks and valuations. Sign up today!View details of Axion Biosystems's funding rounds and investors
Axion Biosystems' founders and board of directors
Founder? Claim ProfileAxion Biosystems' employee count trend
Axion Biosystems has 121 employees as of Apr 26. Here is Axion Biosystems's employee count trend over the years:
Uncover Axion Biosystems' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Axion Biosystems's Competitors and alternates
Top competitors of Axion Biosystems include 10X Genomics, Mission Bio and LUMICKS. Here is the list of Top 10 competitors of Axion Biosystems, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | 10X Genomics 2012, Pleasanton (United States), Public | Developer of single-cell, spatial, and in situ tools for high-resolution biological analysis | $243M | 77/100 | |
2nd | Mission Bio 2014, San Francisco (United States), Series C | Provider of single cell multiomics platform for genotypic and phenotypic analysis | $120M | 65/100 | |
3rd | LUMICKS 2014, Amsterdam (Netherlands), Series D | Manufacturer of optical tweezers for single molecule analysis instruments | $93.4M | 63/100 | |
4th |  Atrandi Biosciences 2016, Vilnius (Lithuania), Series A | A life sciences tool company transforming single-cell research with its patented Semi-Permeable Capsule(SPC) technology, enabling high-throughput and multi-step workflows | $31M | 63/100 | |
5th | One Biosciences 2020, Paris (France), Series A | Developer of single-cell therapeutics solutions to treat multiple health disorders | $22.4M | 61/100 | |
6th |  Xcell Biosciences 2012, San Francisco (United States), Series B | Developer of cell culture analysis device for cancer research | $40.9M | 60/100 | |
7th | Biolog 1984, Hayward (United States), Series A | Provider of cell-based phenotyping technologies and assays | $33.6M | 58/100 | |
8th | IsoPlexis 2012, New Haven (United States), Acquired | Developer of multiplexed single-cell analysis tools for the diagnostics and life science research | $186M | 53/100 | |
9th | Axion Biosystems 2007, Atlanta (United States), Acquired | Develops multi-electrode array technology to provide access to cellular information analysis | $20.3M | 53/100 | |
10th | LevitasBio 2017, San Francisco (United States), Series C | Developer of single-cell imaging and profiling platform based on magnetic levitation technology | $73.8M | 49/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Axion Biosystems's competitors? Click here to see the top ones
Axion Biosystems's Investments and acquisitions
Axion Biosystems has acquired Msolv. Axion Biosystems has not made any investments as of now.Reports related to Axion Biosystems
Here is the latest report on Axion Biosystems's sector:
News related to Axion Biosystems
Filter this listMedia has covered Axion Biosystems for a total of 3 events in the last 1 year.
•
Axion BioSystems and Agilent Technologies Resolve LitigationBusiness Wire•Apr 21, 2026•Axion Biosystems, Agilent
•
Maestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND ProgramBusiness Wire•Feb 18, 2026•Axion Biosystems
•
•
•
•
Water Street Appoints Kevin Gould as Executive AdvisorWater Street•May 14, 2024•Water Street, Axion Biosystems
•
Axion Biosystems Adds Affordable Maestro Volt™ To Its Industry-leading Mea System LineupBusiness Wire•Apr 30, 2024•Axion Biosystems
•
Axion BioSystems Welcomes Biotech Industry Leader Julien Bradley as New CEOBusiness Wire•Oct 05, 2023•Axion Biosystems, RedShift
•
•
CytoSMART Technologies Joins the Axion BioSystems BrandACROFAN•Jan 23, 2023•CytoSMART, Axion Biosystems
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Axion Biosystems
Explore our recently published companies
